嗜黏蛋白阿克曼菌与肥胖相关代谢性疾病的研究进展  

Research Progress of Akkermansia Muciniphila and Obesity-related Metabolic Diseases

作　　者：周洪江 唐娟[1] 梁磊 念馨[1] ZHOU Hongjiang;TANG Juan;LIANG Lei;NIAN Xin(Dept.of Endocrinology,The 1st Affiliated Hospital of Kunming Medical University,Kunming Yunnan 650032,China)

机构地区：[1]昆明医科大学第一附属医院内分泌科,云南昆明650032

出　　处：《昆明医科大学学报》2022年第1期157-162,共6页Journal of Kunming Medical University

基　　金：国家自然科学基金资助项目(81660153);云南省卫生和计划生育委员会医学学科带头人培养计划基金资助项目(D-2017041)。

摘　　要：肠道微生物群在调节宿主免疫和能量代谢等方面起着至关重要的作用,与肥胖、糖尿病以及心血管疾病等疾病的发生有关。目前,多种动物模型和人体研究证明,嗜黏蛋白阿克曼菌(Akkermansia muciniphila/A.muciniphila)水平与肥胖、糖尿病、肥胖性肝病、动脉粥样硬化等代谢性疾病的发生呈负相关。A.muciniphila通过增加肠道黏液层厚度、减轻全身炎症、改善糖耐量和胰岛素抵抗,在治疗代谢紊乱方面具有广阔前景,被认为是新一代的治疗药物。就A.muciniphila与代谢性疾病及宿主之间相互作用的基本机制作系统性综述。The intestinal microbiota plays a vital role in regulating host immunity and energy metabolism,and is related to the occurrence of obesity,diabetes,and cardiovascular diseases.At present,various animal models and human studies have proved that Akkermansia muciniphila(Akkermansia muciniphila/A.muciniphila)levels are negatively correlated with the occurrence of metabolic diseases such as obesity,diabetes,obese liver disease,and atherosclerosis.A.muciniphila has broad prospects in the treatment of metabolic disorders by increasing the thickness of the intestinal mucus layer,reducing systemic inflammation,improving glucose tolerance and insulin resistance,and is considered to be a new generation of therapeutic drugs.This article systematically reviews the basic mechanism of the interaction between A.muciniphila and metabolic diseases and hosts.

关 键 词：嗜黏蛋白阿克曼菌 肠道屏障 全身炎症 胰岛素抵抗 

分 类 号：R589.2[医药卫生—内分泌]